- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00006249
Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma
PEG-Intron Observation After Regional Lymph Node Dissection in AJCC Stage III (TxN1-2MO) Melanoma Patients: a Randomized Phase III Trial
RATIONALE: Interferon alfa may interfere with the growth of the cancer cells. It is not yet known if this treatment is more effective than observation following surgery for stage III melanoma.
PURPOSE: Randomized phase III trial to determine the effectiveness of interferon alfa in treating patients who have undergone surgery for stage III melanoma.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
OBJECTIVES:
- Compare the effect of adjuvant therapy with pegylated interferon alfa vs observation, in terms of distant metastases-free survival, in patients with previously resected stage III melanoma.
- Compare the overall survival in these patients after treatment with pegylated interferon alfa vs observation.
- Determine the toxicity of pegylated interferon alfa in these patients.
- Determine the compliance of these patients treated with pegylated interferon alfa.
- Compare the quality of life in these patients after treatment with pegylated interferon alfa vs observation.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to type of nodal involvement (N1 vs N2), number of positive nodes (1 vs 2-4 vs 5 or more vs not assessed), Breslow primary (T1-2 vs T3 vs T4 vs unknown), ulceration of primary tumor (absent vs present vs unknown), sex, and center. Patients are randomized to one of two treatment arms.
- Arm I: Patients receive pegylated interferon alfa subcutaneously weekly for 5 years.
- Arm II: Patients undergo observation only. Treatment continues in the absence of distant metastases or unacceptable toxicity.
Quality of life is assessed at baseline, and then at months 3, 12, 24, 36, 48, and 60.
Patients are followed every 6 months for 5 years.
PROJECTED ACCRUAL: A total of 1,200 patients (600 per treatment arm) will be accrued for this study within 1.5-2 years.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Berlin, Alemania, D-13122
- Robert Roessle Klinik
-
Bochum 1, Alemania, D-44791
- Saint Josef Hospital
-
Dortmund, Alemania, 44123
- Stadt. Kliniken
-
Erlangen, Alemania, D-91054
- Universitaet Erlangen
-
Goettingen, Alemania, D-37075
- Georg August Universitaet
-
Hamburg, Alemania, D-22765
- Haematologisch-Onkologische Praxis Altona
-
Heidelberg, Alemania, D-69115
- Universitaets-Hautklinik Heidelberg
-
Leipzig, Alemania, D-04103
- Universitaet Leipzig - Chirurgische Klinik und Poliklinik I
-
Magdeburg, Alemania, D-39120
- Otto - Von - Guericke - Universitaet Magdeburg
-
Mannheim, Alemania, D-68135
- Klinikum der Stadt Mannheim
-
Wuerzburg, Alemania, D-97080
- Universitaet Wuerzburg/Hautkrankheiten
-
-
-
-
-
Newcastle, Australia, NSW 2300
- David Maddison Clincial Sciences
-
-
Victoria
-
East Melbourne, Victoria, Australia, 8006
- Peter MacCallum Cancer Institute
-
Heidelberg West, Victoria, Australia, 3081
- Austin and Repatriation Medical Centre
-
-
Western Australia
-
Perth, Western Australia, Australia, 6000
- Royal Perth Hospital
-
Perth, Western Australia, Australia, 6009
- Sir Charles Gairdner Hospital, Perth
-
-
-
-
-
Sofia, Bulgaria, 1756
- National Centre of Oncology
-
-
-
-
-
Brussels, Bélgica, 1200
- Cliniques universitaires Saint-Luc
-
Brussels, Bélgica, 1000
- Institut Jules Bordet
-
Brussels, Bélgica, 1070
- Hopital Universitaire Erasme
-
Edegem, Bélgica, B-2650
- Universitair Ziekenhuis Antwerpen
-
Gosselies, Bélgica, 6041
- Clinique Notre Dame de Grâce
-
Leuven, Bélgica, B-3000
- U.Z. Gasthuisberg
-
-
-
-
-
Zagreb, Croacia, 10000
- University Hospital Sestre milosrdnice
-
-
-
-
-
Ljubljana, Eslovenia, Sl-1000
- Institute of Oncology, Ljubljana
-
-
-
-
-
Madrid, España, 28041
- Hospital Universitario 12 de Octubre
-
Zaragoza, España, 50009
- Hospital Clinico Universitario
-
-
-
-
-
Tallinn, Estonia, 11619
- North-Estonian Regional Hospital Cancer Centre
-
-
-
-
-
Amiens, Francia, 80054
- Centre Hospitalier Universitare d'Amens
-
Besancon, Francia, 25030
- CHR de Besancon - Hopital Saint-Jacques
-
Bordeaux, Francia, 33075
- Hopital Saint André
-
Boulogne Billancourt, Francia, F-92104
- CHU Ambroise Pare
-
Grenoble, Francia, 38043
- Chr De Grenoble - La Tronche
-
Lille, Francia, 59037
- Centre Hospitalier Regional et Universitaire de Lille
-
Limoges, Francia, 87042
- Centre Hospital Regional Universitaire de Limoges
-
Lyon, Francia, 69373
- Centre Leon Berard
-
Montpellier, Francia, 34298
- Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
-
Montpellier, Francia, 34295
- Hopital St. Eloi
-
Nice, Francia, F-06202
- Hopital L'Archet - 2
-
Paris, Francia, 75018
- Hôpital Bichat - Claude Bernard
-
Paris, Francia, 75475
- Hôpital Saint-Louis
-
Pessac, Francia, 33604
- Hôpital Haut Leveque
-
Reims, Francia, 51092
- Centre Hospitalier Universitaire
-
Rennes, Francia, 35042
- Centre Eugène Marquis
-
Saint Cloud, Francia, 92211
- Centre René Huguenin
-
Saint Priest en Jarez, Francia, 42277
- Centre Hospitalier Regional et Universitaire de Saint-Etienne
-
Strasbourg, Francia, 67091
- Hopitaux Universitaire de Strasbourg
-
Thionville, Francia, 57126
- Centre Hospitalier Regional Metz Thionville
-
Tours, Francia, 37044
- Centre Hospitalier Universitaire Bretonneau de Tours
-
Vandoeuvre-les-Nancy, Francia, 54511
- Centre Alexis Vautrin
-
Villejuif, Francia, F-94805
- Institut Gustave Roussy
-
-
-
-
-
Haifa, Israel, 31096
- Rambam Medical Center
-
Holon, Israel, 58100
- Wolfson Medical Center
-
Tel-Aviv, Israel, 64239
- Tel-Aviv Sourasky Medical Center
-
-
-
-
-
Aviano, Italia, 33081
- Centro di Riferimento Oncologico - Aviano
-
Firenze, Italia, I-50011
- Ospendale S.M. Annunziata-A.S.DI Firenze
-
Genoa (Genova), Italia, 16132
- Istituto nazionale Per la Ricerca sul Cancro
-
Milano, Italia, 20141
- European Institute of Oncology - Chemo Prevention
-
Milano (Milan), Italia, 20133
- Istituto Nazionale Per Lo Studio E La Cura Dei Tumori
-
Naples, Italia, 80131
- Istituto Nazionale Per Lo Studio E La Cura Dei Tumori
-
Rome, Italia, 00161
- Istituto Regina Elena
-
Torino, Italia, 10126
- Universita degli Studi di Torino
-
-
-
-
-
Istanbul, Pavo, 34296
- Vakif Gureba Training Hospital
-
Izmir, Pavo, 35220
- Ege University Medical School
-
-
-
-
-
Amsterdam, Países Bajos, 1007 MB
- Vrije Universiteit Medisch Centrum
-
Leiden, Países Bajos, 2300 CA
- Leiden University Medical Center
-
Nijmegen, Países Bajos, NL-6500 HB
- University Medical Center Nijmegen
-
Rotterdam, Países Bajos, 3075 EA
- Erasmus University Medical Center
-
Utrecht, Países Bajos, 3584 CX
- Academisch Ziekenhuis Utrecht
-
-
-
-
-
Poznan, Polonia, 61 866
- Great Poland Cancer Center
-
Warsaw, Polonia, 02-781
- Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
-
-
-
-
-
Lisbon, Portugal, 1099-023 Codex
- Instituto Portugues de Oncologia de Francisco Gentil - Centro de Lisboa
-
Porto, Portugal, 4200
- Instituto Portugues de Oncologia Centro do Porto, SA
-
-
-
-
-
Birmingham, Reino Unido, B29 6JD
- Selly Oak Hospital at University Hospital NHS Trust
-
Oxford, Reino Unido, OX3 7LJ
- Churchill Hospital
-
-
England
-
Bristol, England, Reino Unido, BS2 8ED
- Bristol Haematology and Oncology centre
-
Cambridge, England, Reino Unido, CB2 2QQ
- Addenbrooke's NHS Trust
-
Cheltenham, England, Reino Unido, GL53 7AN
- Cheltenham General Hospital
-
Exeter, England, Reino Unido, EX2 5DW
- Royal Devon and Exeter Hospital
-
Guildford, England, Reino Unido, GU2 5XX
- Royal Surrey County Hospital
-
Hull, England, Reino Unido, HU8 9HE
- Princess Royal Hospital
-
Leeds, England, Reino Unido, LS9 7TF
- St. James's Hospital
-
Leicester, England, Reino Unido, LE1 5WW
- Leicester Royal Infirmary
-
London, England, Reino Unido, SW3 6JJ
- Royal Marsden NHS Trust
-
London, England, Reino Unido, NW3 2QG
- Royal Free Hospital
-
London, England, Reino Unido, SW17 0QT
- St. George's Hospital
-
London, England, Reino Unido, EC1A 7BE
- Saint Bartholomew's Hospital
-
London, England, Reino Unido, SE1 9RT
- Guy's and St. Thomas' Hospitals NHS Trust
-
Merseyside, England, Reino Unido, CH63 4JY
- Clatterbridge Centre for Oncology NHS Trust
-
Newcastle Upon Tyne, England, Reino Unido, NE4 6BE
- Newcastle General Hospital
-
Salisbury, England, Reino Unido, SP2 8BJ
- Salisbury District Hospital
-
Sheffield, England, Reino Unido, S1O 2SJ
- Weston Park Hospital
-
Southampton, England, Reino Unido, SO16 6YD
- Southampton General Hospital
-
Sutton, England, Reino Unido, SM2 5PT
- Royal Marsden Hospital
-
Westcliff-On-Sea, England, Reino Unido, SS0 0RY
- Southend NHS Trust Hospital
-
-
Northern Ireland
-
Belfast, Northern Ireland, Reino Unido, BT9 7AB
- Belfast City Hospital Trust
-
-
Scotland
-
Dundee, Scotland, Reino Unido, DD1 9SY
- Ninewells Hospital and Medical School
-
Glasgow, Scotland, Reino Unido, G11 6NT
- Western Infirmary
-
-
Wales
-
Cardiff, Wales, Reino Unido, CF4 7XL
- Velindre Cancer Center at Velinde Hospital
-
-
-
-
-
Prague (Praha), República Checa, 128 08
- Charles University Hospital
-
-
-
-
-
Aarau, Suiza, 5001
- Kantonspital Aarau
-
Bern, Suiza, CH-3010
- Inselspital, Bern
-
Chur, Suiza, CH-7000
- Ratisches Kantons und Regionalspital
-
Zurich, Suiza, CH-8091
- UniversitaetsSpital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
DISEASE CHARACTERISTICS:
Histologically confirmed previously resected stage III primary cutaneous melanoma or unknown primary with regional lymph node involvement
N1 disease
- Microscopic, nonpalpable nodal involvement
- Primary melanoma of any stage with clinically inapparent N1 regional lymph node metastases (T1-4, N1, M0) detected by elective lymph node dissection or sentinel node biopsy
N2 disease
- Palpable nodal involvement with synchronous primary melanoma or apparent nodal disease after prior excision (any pT, N2, M0)
- Regional lymph node recurrence at any interval after surgery for primary melanoma of any depth (T1-4, rN2, M0)
- Complete resection of primary melanoma with adequate surgical margins
- Full lymphadenectomy must be performed within 70 days of study
- No mucous membrane melanoma or ocular melanoma
- No evidence of distant or nonregional lymph node metastases or in transit metastases (even if previously resected)
- No incompletely resected disease due to gross extracapsular extension
PATIENT CHARACTERISTICS:
Age:
- 18 to 70
Performance status:
- ECOG 0-1
Life expectancy:
- Not specified
Hematopoietic:
- WBC at least 3,000/mm^3
- Platelet count greater than 100,000/mm^3
- Hemoglobin at least 9 g/dL
Hepatic:
- SGOT and SGPT less than 2 times upper limit of normal
- No active hepatitis
Renal:
- Creatinine less than 2.0 mg/dL
Cardiovascular:
No severe cardiovascular disease including the following:
- Arrhythmias requiring chronic treatment
- Congestive heart failure (New York Heart Association class III or IV)
- Symptomatic ischemic heart disease
Other:
- No other prior malignancy within the past 5 years except surgically cured nonmelanomatous skin cancer or carcinoma in situ of the cervix
- No thyroid dysfunction unresponsive to therapy
- No uncontrolled diabetes mellitus
- No active autoimmune disease
- No active and/or uncontrolled infection
- No history of neuropsychiatric disorder requiring hospitalization
- No known active alcohol or drug abuse
- HIV negative
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- No prior interferon alfa
- No prior immunotherapy for melanoma
- No other concurrent immunologic or biologic therapy
- No concurrent colony stimulating factors including epoetin alfa and filgrastim (G-CSF)
Chemotherapy:
- No prior chemotherapy for melanoma
- No concurrent chemotherapy
Endocrine therapy:
- No prior hormonal therapy for melanoma
- No concurrent hormonal therapy
- No concurrent chronic systemic corticosteroid therapy
Radiotherapy:
- No prior radiotherapy for melanoma
- No concurrent radiotherapy
Surgery:
- See Disease Characteristics
- Recovered from any prior recent surgery
Other:
- At least 30 days since other prior experimental therapy
- No other concurrent investigational drugs
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Sin intervención: observation
5 years observation + 5 years follow up
|
|
Experimental: pegylated interferon alfa
5 years pegylated interferon alfa + 5 years follow up
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
distant-metastasis free-survival (DMFS)
Periodo de tiempo: from randomization
|
distant-metastasis free-survival (DMFS) after randomization
|
from randomization
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
survival
Periodo de tiempo: from randomization till death
|
duration of survival: time from randomization until death, whatever the cause
|
from randomization till death
|
toxicity
Periodo de tiempo: from randomization
|
toxicity
|
from randomization
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
quality of life
Periodo de tiempo: from randomization
|
Quality of life evaluation
|
from randomization
|
Colaboradores e Investigadores
Investigadores
- Silla de estudio: Alexander M. M. Eggermont, MD, PhD, Daniel Den Hoed Cancer Center at Erasmus Medical Center
Publicaciones y enlaces útiles
Publicaciones Generales
- Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, Santinami M, Sales F, Schadendorf D, Patel P, Dummer R, Robert C, Keilholz U, Yver A, Spatz A. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer. 2012 Jan;48(2):218-25. doi: 10.1016/j.ejca.2011.09.028. Epub 2011 Nov 5.
- Eggermont AM, Suciu S, Santinami M, et al.: EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-α2b (PEG-IFN) versus observation in resected stage III melanoma: long-term results at 7.6-years follow-up. [Abstract] J Clin Oncol 29 (Suppl 15): A-8506b, 2011.
- Bouwhuis MG, Suciu S, Testori A, Kruit WH, Sales F, Patel P, Punt CJ, Santinami M, Spatz A, Ten Hagen TL, Eggermont AM. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991. J Clin Oncol. 2010 May 10;28(14):2460-6. doi: 10.1200/JCO.2009.24.6264. Epub 2010 Apr 12.
- Eggermont AM, Bouwhuis MG, Kruit WH, Testori A, ten Hagen T, Yver A, Xu C. Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991). Cancer Chemother Pharmacol. 2010 Mar;65(4):671-7. doi: 10.1007/s00280-009-1072-z. Epub 2009 Jul 21.
- Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, Marsden J, Punt C, Sales F, Gore M, Mackie R, Kusic Z, Dummer R, Patel P, Schadendorf D, Spatz A, Keilholz U, Eggermont A. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2009 Jun 20;27(18):2916-23. doi: 10.1200/JCO.2008.20.2069. Epub 2009 May 11. Erratum In: J Clin Oncol. 2009 Sep 20;27(27):4630. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.
- Fusi A, Collette S, Busse A, Suciu S, Rietz A, Santinami M, Kruit WH, Testori A, Punt CJ, Dalgleish AG, Spatz A, Eggermont AM, Keilholz U. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). Eur J Cancer. 2009 Dec;45(18):3189-97. doi: 10.1016/j.ejca.2009.09.004. Epub 2009 Sep 28.
- Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Sales F, Gore M, MacKie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U; EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008 Jul 12;372(9633):117-126. doi: 10.1016/S0140-6736(08)61033-8.
- Eggermont AM, Suciu S, Santinami M, et al.: EORTC 18991: long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-8504, 473s, 2007.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias por tipo histológico
- Neoplasias
- Tumores neuroectodérmicos
- Neoplasias De Células Germinales Y Embrionarias
- Neoplasias De Tejido Nervioso
- Tumores neuroendocrinos
- Nevos y Melanomas
- Melanoma
- Efectos fisiológicos de las drogas
- Agentes antiinfecciosos
- Agentes Antivirales
- Agentes antineoplásicos
- Factores inmunológicos
- Interferones
- Interferón-alfa
Otros números de identificación del estudio
- EORTC-18991
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre terapia adyuvante
-
NeuroTronik Inc.DesconocidoInsuficiencia cardiaca | Insuficiencia cardíaca agudaParaguay
-
University of Roma La SapienzaTerminadoImplante dental fallido | Mucositis BucalItalia
-
NeuroTronik Inc.DesconocidoTerapia de estimulación autónoma del gasto cardíaco para la insuficiencia cardíaca aguda (COAST-AHF)Insuficiencia cardíaca agudaPanamá
-
Vyaire MedicalAún no reclutandoSíndrome de insuficiencia respiratoria del recién nacidoItalia
-
Boston Children's HospitalTerminadoEstrés Psicológico | Problema de aculturaciónEstados Unidos
-
Abbott Medical DevicesTerminadoFlutter auricular típicoEstados Unidos, Canadá
-
Abbott Medical DevicesTerminadoFibrilación auricular paroxísticaAustralia, Alemania, Francia, Italia, Portugal, Reino Unido
-
Abbott Medical DevicesTerminado
-
Northwestern UniversityNeuroneticsTerminadoDepresión | Ansiedad | Cáncer en remisión (cualquier tipo o etapa)Estados Unidos